Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

After-Hours Movers: Coupa Software Jumps on Strong EPS, UiPath Falls

Published 09/07/2022, 05:38 AM
© Reuters.
HOG
-
NWL
-
GWRE
-
ELDN
-
MEDP
-
COUP
-
AQST
-
PATH
-
PYCR
-
CRGY
-

After-Hours Stock Movers:

UiPath Inc. (PATH) 16% LOWER; reported Q2 EPS of ($0.02), $0.09 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $242.2 million versus the consensus estimate of $230.64 million. UiPath Inc. sees Q3 2023 revenue of $243-245 million, versus the consensus of $269.6 million. UiPath Inc. sees FY2023 revenue of $1.002-1.007 billion, versus the consensus of $1.09 billion.

Coupa Software (NASDAQ:COUP) 13% HIGHER; reported Q2 EPS of $0.20, $0.11 better than the analyst estimate of $0.09. Revenue for the quarter came in at $211 million versus the consensus estimate of $203.83 million. Announces Board of Directors Authorized $100 Million Share Repurchase Program. Coupa Software sees Q3 2023 EPS of $0.08-$0.10, versus the consensus of $0.06. Coupa Software sees Q3 2023 revenue of $211-214 million, versus the consensus of $214 million. Coupa Software sees FY2023 EPS of $0.37-$0.44, versus the consensus of $0.26. Coupa Software sees FY2023 revenue of $838-844 million, versus the consensus of $840.3 million.

Aquestive Therapeutics (NASDAQ:AQST) 10% HIGHER; Oppenheimer initiates coverage with an Outperform rating and a price target of $8.50.

Crescent Energy Company (CRGY) 6% LOWER; announced the commencement of an underwritten public offering of 5,000,000 shares of its Class A common stock,

Eledon Pharmaceuticals, Inc. (ELDN) 6% HIGHER; announced that the U.S. Food and Drug Administration (FDA) has cleared the company's Investigational New Drug (IND) application to evaluate tegoprubart for the treatment of IgA Nephropathy (IgAN).

Newell Brands (NWL) 3% LOWER; warns for Q3 and FY. The company sees Q3 net sales of $2.21-$2.32 billion, versus prior guidance of $2.39-$2.5 billion and the consensus of $2.52 billion. The company sees EPS of $0.46-$0.51, versus prior of $0.50-$0.54, and the consensus of $0.53. The company sees FY net sales of $9.37-$9.58 billion, versus prior guidance of $9.76-$9.98 billion and the consensus of $9.89 billion. The company sees FY EPS of $1.56-$1.70, versus prior guidance of $1.79-$1.86 and the consensus of $1.84.

Paycor HCM, Inc. (Nasdaq: PYCR) 3% LOWER; announced the commencement of an underwritten public offering of 5,000,000 shares of common stock on behalf of investment funds advised by Apax Partners LLP.

Guidewire Software (NYSE:GWRE) 2% HIGHER; reported Q4 EPS of $0.03, $0.04 better than the analyst estimate of ($0.01). Revenue for the quarter came in at $244.6 million versus the consensus estimate of $229.57 million. Guidewire Software sees Q1 2023 revenue of $190-195 million, versus the consensus of $187.7 million. Guidewire Software sees FY2023 revenue of $885-895 million, versus the consensus of $882 million.

Medpace Holdings (NASDAQ:MEDP) 2% HIGHER; CEO, August Troendle via Medpace Investors, LLC, bought 90,790 shares from 09/01/22-09/02/22 at prices from $144.52-$144.98, bringing the firm's stake to 5,604,429 shares. Troendle also owns 806,643 shares directly.

Harley-Davidson (NYSE:HOG) 1.3% HIGHER; President/CEO, Jochen Zeitz, bought 25,750 shares on 09/02/22 at $38.94. The value of the purchase was over $1 billion.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.